Array: Analysts Predict a Bright Future
Solar tracker giant Array got Buy ratings and $11 price targets. Focus on utility-scale and turnaround boosted confidence.
NOTRELOAD AI
Major Buy Signal! Jefferies Initiates Coverage on Nuvation Bio
Jefferies issued a Buy rating on Nuvation Bio with a $10 price target, citing its FDA-approved lead drug, strong pipeline potential, and cash reserves extending into 2028.
Goldman Sachs Downgrades Spotify to Neutral on Stock Risk/Reward
Goldman Sachs cut Spotify's stock rating to "Neutral" (from "Buy"). They think the stock price already reflects its strong future revenue growth.
Wolfspeed's Dramatic Return: Cutting $4.6 Billion in Debt and Reshaping the Stock Structure
Wolfspeed successfully exited bankruptcy, now financially stronger after slashing 70% of debt and 60% of interest costs.
AnaptysBio Plans to Split into Two Independent Companies
AnaptysBio announced plans to separate its business into 'Royalty Management Co' and 'Biopharma Co' by late 2026, aiming to unlock the potential value of its immunology pipeline and royalty assets.
FDA Scrutinizes Aurinia's Voclosporin Toxicity and Surrogate Endpoints
A top FDA official flagged the drug voclosporin as highly toxic, noting it was approved too quickly using ‘stand-in’ results (surrogate endpoints) without proving a direct benefit to patients. The FDA will now review this process to ensure approved drugs deliver real clinical results.